



Caribou Biosciences to Participate in Upcoming Investor Conferences

February 15, 2024

BERKELEY, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- [Caribou Biosciences, Inc.](#) (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company's participation in the following investor conferences:

- Citi's 2024 Virtual Oncology Leadership Summit
February 21, 2024, fireside chat at 12:00 pm EST
- Leerink Global Biopharma Conference
March 12, 2024, fireside chat at 1:40 pm EDT
- Barclays Global Healthcare Conference
March 13, 2024
- H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
March 26, 2024, fireside chat at 11:30 am EDT

For more information and links to available webcasts, visit the [Events](#) page on Caribou's website. Webcasts will be available on the Caribou website for 30 days after the events.

About Caribou's novel next-generation CRISPR platform

CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNA; pronounced "chardonnays") that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA technology to carry out high efficiency multiple edits, including multiplex gene insertions, to develop CRISPR-edited therapies.

About Caribou Biosciences, Inc.

Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company's genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve antitumor activity. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T and CAR-NK platforms as readily available treatments for patients with hematologic malignancies and solid tumors. Follow us @CaribouBio and visit www.cariboubio.com.

Caribou Biosciences, Inc. contacts:

Investors:

Amy Figueroa, CFA
investor.relations@cariboubio.com

Media:

Peggy Vorwald, PhD
media@cariboubio.com